Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

L.A. McKeown

June 24, 2025

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

Semaglutide Winning Streak Continues in CKD With FLOW

Shelley Wood

March 06, 2024

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

AHA Seeks to Drive Down Amputations 20% by 2030

L.A. McKeown

April 01, 2021

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Features

Top News in Heart Failure: 2018

Shelley Wood

December 28, 2018

News Daily News

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

Michael O'Riordan

November 23, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Drug Company Payments to Physicians May Be Influencing Prescribing

Todd Neale

August 23, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Industry News

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

May 06, 2016

News Industry News

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

March 06, 2016

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

Amylin Analogue Boosts Weight Loss When Added to GLP-1

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

Semaglutide Winning Streak Continues in CKD With FLOW

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

AHA Seeks to Drive Down Amputations 20% by 2030

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Top News in Heart Failure: 2018

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Drug Company Payments to Physicians May Be Influencing Prescribing

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content